Angiomyolipoma: Clinical Trials

3 trials for Angiomyolipoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 completed, 1 recruiting, 1 withdrawn. 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 23Completed 1, Recruiting 1, Withdrawn 1

Follow Angiomyolipoma: new trials by email Literature Review of Angiomyolipoma trials Research Report on Angiomyolipoma

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Ivonescimab in the Treatment of Multiple Advanced Tumors
Ivocizumab - Pheochromocytoma/Paraganglioma, Rhabdomyosarcoma
Phase 2RecruitingFudan University4002024-11-202025-08-24
A Phase II Study of Orally Administered BEZ235 Monotherapy in Patients With Metastatic or Unresectable Malignant PEComa
BEZ235 - Malignant PEComa (Perivascular Epithelioid Cell Tumors)
Phase 2WithdrawnNovartis Pharmaceuticals2012-09-012013-08-02
RAPAMYCIN FOR KIDNEY ANGIOMYOLIPOMAS
Rapamycin - Nonmalignant Neoplasm, Tuberous Sclerosis
Phase 2CompletedDana-Farber Cancer Institute362005-12-202022-04-25

Narrower conditions

Perivascular Epithelioid Cell Neoplasms (2)  ·  Tuberous Sclerosis (2)  ·  Carcinoma (1)  ·  Carcinoma, Basal Cell (1)  ·  Carcinoma, Neuroendocrine (1)  ·  Carcinoma, Transitional Cell (1)  ·  Kidney Neoplasms (1)  ·  Neoplasms (1)  ·  Paget Disease, Extramammary (1)  ·  Paraganglioma (1)  ·  Penile Neoplasms (1)  ·  Pheochromocytoma (1)  ·  Prostatic Neoplasms (1)  ·  Rhabdomyosarcoma (1)

Broader conditions

Neoplasms by Histologic Type (3)  ·  Neoplasms, Adipose Tissue (3)  ·  Neoplasms, Connective and Soft Tissue (3)  ·  Congenital Abnormalities (2)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2)  ·  Genetic Diseases, Inborn (2)  ·  Hamartoma (2)  ·  Heredodegenerative Disorders, Nervous System (2)  ·  Malformations of Cortical Development (2)  ·  Malformations of Cortical Development, Group I (2)  ·  Neoplasms (2)  ·  Neoplasms, Multiple Primary (2)  ·  Neoplastic Syndromes, Hereditary (2)  ·  Nervous System Diseases (2)  ·  Nervous System Malformations (2)

Interventions

Sirolimus (1)  ·  dactolisib (1)

Sponsors

Dana-Farber Cancer Institute (1)  ·  Fudan University (1)  ·  Novartis Pharmaceuticals (1)

Countries

China (1)  ·  Spain (1)  ·  United States (1)

Top investigators

Hongxia Wang, Doctor (1)  ·  Sandra Dabora, MD, PhD (1)

Results publications

PMID 21915260, PMID 23437092

NIH funding

P30CA006516 (1), R01CA107164 (1)